Mega Lifesciences has interacted with stakeholders in various forms including analyst reports, shareholder meetings both annual as well as quarterly, opportunity day interaction, regulatory changes, employee feedbacks on policies and work environment, supplier inputs by Supply Chain team and customer interaction by sales teams.

Considering the key concerns expressed and raised by all the stake holders Mega Lifesciences has identified its key concerns or material concerns which need to be addressed to ensure Mega remains a sustainable company and truly as per Mega’s thinking continues to live and grow beyond all of us at Mega. Mega Lifesciences has on a regular basis conveyed the concerns to the Board of Directors and the Company’s strategy has been greatly influenced by the Material concerns from stakeholders.

Economic Dimension

C1
Corporate Governance
C2
Risk Management
C3
Sustainable sourcing
C4
Responsible business practices
C5
Information Technology
C6
Affordable and Innovation Medicines
C7
Anti-Corruption
C8
Combatting Counterfeit Drug/Enforcement

Environment Dimension

V1
Waste Management
V2
Water Management
V3
Energy Management
V4
Compliance with Environment laws
V5
Community engagement

Social Dimension

S1
Attracting and retaining Talent
S2
Training and Development
S3
Diversity
S4
Human Rights
S5
Non-Discrimination and no harassment
S6
Community development